Geert M Raes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6733348/publications.pdf

Version: 2024-02-01

98 papers	6,852 citations	57719 44 h-index	62565 80 g-index
99 all docs	99 docs citations	99 times ranked	9922 citing authors

#	Article	IF	Citations
1	Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nature Communications, 2016, 7, 10321.	5.8	604
2	Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor Î°B. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14978-14983.	3.3	551
3	Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion. Immunobiology, 2006, 211, 487-501.	0.8	309
4	Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. Journal of Leukocyte Biology, 2002, 71, 597-602.	1.5	302
5	Nanobody-Based Targeting of the Macrophage Mannose Receptor for Effective In Vivo Imaging of Tumor-Associated Macrophages. Cancer Research, 2012, 72, 4165-4177.	0.4	263
6	Alternatively activated macrophages during parasite infections. Trends in Parasitology, 2004, 20, 126-133.	1.5	261
7	Arginase-1 and Ym1 Are Markers for Murine, but Not Human, Alternatively Activated Myeloid Cells. Journal of Immunology, 2005, 174, 6561-6562.	0.4	249
8	Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. Journal of Leukocyte Biology, 2005, 77, 321-327.	1.5	216
9	Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. Frontiers in Immunology, 2014, 5, 489.	2.2	163
10	Identification of a common gene signature for type II cytokineâ€“associated myeloid cells elicited in vivo in different pathologic conditions. Blood, 2006, 108, 575-583.	0.6	155
11	PET Imaging of Macrophage Mannose Receptorâ€“Expressing Macrophages in Tumor Stroma Using ¹⁸F-Radiolabeled Camelid Single-Domain Antibody Fragments. Journal of Nuclear Medicine, 2015, 56, 1265-1271.	2.8	139
12	Reactive Oxygen Species and 12/15-Lipoxygenase Contribute to the Antiproliferative Capacity of Alternatively Activated Myeloid Cells Elicited during Helminth Infection. Journal of Immunology, 2005, 174, 6095-6104.	0.4	126
13	131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment. Clinical Cancer Research, 2017, 23, 6616-6628.	3.2	124
14	FIZZ1 and Ym as Tools to Discriminate between Differentially Activated Macrophages. Autoimmunity, 2002, 9, 151-159.	0.6	118
15	Peroxisome proliferator-activated receptor Î³ (PPARÎ³) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood, 2006, 108, 525-535.	0.6	114
16	Myeloidâ€derived suppressor cells in parasitic infections. European Journal of Immunology, 2010, 40, 2976-2985.	1.6	107
17	In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT. Journal of Nuclear Medicine, 2010, 51, 1099-1106.	2.8	106
18	Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types. Journal of Nuclear Medicine, 2010, 51, 782-789.	2.8	102

#	Article	IF	Citations
19	Expression of the Inhibitory CD200 Receptor Is Associated with Alternative Macrophage Activation. Journal of Innate Immunity, 2010, 2, 195-200.	1.8	99
20	Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells. Journal of Immunology, 2003, 170, 5064-5074.	0.4	95
21	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget, 2017, 8, 41932-41946.	0.8	95
22	Alternatively Activated Myeloid Cells Limit Pathogenicity Associated with African Trypanosomiasis through the IL-10 Inducible Gene Selenoprotein P. Journal of Immunology, 2008, 180, 6168-6175.	0.4	92
23	Alternatively activated macrophages in protozoan infections. Current Opinion in Immunology, 2007, 19, 454-459.	2.4	85
24	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics, 2018, 8, 3559-3570.	4.6	85
25	Heterogeneity of macrophage activation in fish. Developmental and Comparative Immunology, 2011, 35, 1246-1255.	1.0	83
26	Theranostics in immuno-oncology using nanobody derivatives. Theranostics, 2019, 9, 7772-7791.	4.6	83
27	SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis. Journal of Nuclear Medicine, 2013, 54, 807-814.	2.8	80
28	Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages. Molecular Imaging and Biology, 2019, 21, 898-906.	1.3	69
29	A Novel Promiscuous Class of Camelid Single-Domain Antibody Contributes to the Antigen-Binding Repertoire. Journal of Immunology, 2010, 184, 5696-5704.	0.4	68
30	Systemic Reprogramming of Monocytes in Cancer. Frontiers in Oncology, 2020, 10, 1399.	1.3	68
31	Phase I Trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients. Journal of Nuclear Medicine, 2021, 62, 1097-1105.	2.8	67
32	Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC: Cardiovascular Imaging, 2019, 12, 2015-2026.	2.3	66
33	Infection Stage-Dependent Modulation of Macrophage Activation in Trypanosoma congolense -Resistant and -Susceptible Mice. Infection and Immunity, 2002, 70, 6180-6187.	1.0	62
34	Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Research, 1995, 55, 2730-3.	0.4	58
35	The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling. Journal of Leukocyte Biology, 2006, 80, 838-849.	1.5	57
36	African trypanosomosis: From immune escape and immunopathology to immune intervention. Veterinary Parasitology, 2007, 148, 3-13.	0.7	57

#	Article	IF	Citations
37	Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Therapy, 2012, 19, 1133-1140.	2.3	55
38	Al¹⁸F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging. Theranostics, 2017, 7, 2924-2939.	4.6	54
39	Transcriptome analysis of monocyte-HIV interactions. Retrovirology, 2010, 7, 53.	0.9	52
40	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. Cancers, 2019, 11, 872.	1.7	50
41	Cellular expression of the cytolytic factor in earthworms Eisenia foetida. Immunology Letters, 1998, 60, 23-29.	1.1	48
42	The role of monocytes in the development of Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome. Immunobiology, 2014, 219, 37-44.	0.8	48
43	IL1Î² Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D. Cancer Immunology Research, 2021, 9, 309-323.	1.6	48
44	Molecular Imaging with Macrophage CRIg-Targeting Nanobodies for Early and Preclinical Diagnosis in a Mouse Model of Rheumatoid Arthritis. Journal of Nuclear Medicine, 2014, 55, 824-829.	2.8	47
45	Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 68Ga-NOTA-anti-MMR nanobody: non-invasive imaging of atherosclerotic plaques. EJNMMI Research, 2019, 9, 5.	1.1	46
46	MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development. PLoS Pathogens, 2014, 10, e1004414.	2.1	45
47	The non-mammalian MIF superfamily. Immunobiology, 2017, 222, 473-482.	0.8	43
48	Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. Biomolecules, 2019, 9, 548.	1.8	43
49	Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood, 2002, 100, 4049-4058.	0.6	42
50	Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation. Biomolecules, 2020, 10, 1388.	1.8	42
51	Mycobacterium-associated immune reconstitution disease: macrophages running wild?. Lancet Infectious Diseases, The, 2006, 6, 2-3.	4.6	40
52	The Central Role of Macrophages in Trypanosomiasis-Associated Anemia:Rationale for Therapeutical Approaches. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2010, 10, 71-82.	0.6	40
53	The role of hepatic macrophages in liver metastasis. Cellular Immunology, 2018, 330, 202-215.	1.4	39
54	Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology, 2012, 217, 1266-1272.	0.8	38

#	Article	IF	Citations
55	Modulation of the complement system in monocytes contributes to tuberculosis-associated immune reconstitution inflammatory syndrome. Aids, 2013, 27, 1725-1734.	1.0	38
56	Monocytes Contribute to Differential Immune Pressure on R5 versus X4 HIV through the Adipocytokine Visfatin/NAMPT. PLoS ONE, 2012, 7, e35074.	1.1	34
57	Targeting of Human Antigen-Presenting Cell Subsets. Journal of Virology, 2013, 87, 11304-11308.	1.5	31
58	Scrutinizing the mechanisms underlying the induction of anemia of inflammation through GPI-mediated modulation of macrophage activation in a model of African trypanosomiasis. Microbes and Infection, 2010, 12, 389-399.	1.0	30
59	Monitoring liver macrophages using nanobodies targeting Vsig4: Concanavalin A induced acute hepatitis as paradigm. Immunobiology, 2015, 220, 200-209.	0.8	27
60	Development of an adenovirus vector vaccine platform for targeting dendritic cells. Cancer Gene Therapy, 2018, 25, 27-38.	2.2	27
61	Novel halfâ€life extended antiâ€MIF nanobodies protect against endotoxic shock. FASEB Journal, 2018, 32, 3411-3422.	0.2	27
62	Beyond the Mâ€<scp>CSF</scp> receptor â€“ novel therapeutic targets in tumorâ€associated macrophages. FEBS Journal, 2018, 285, 777-787.	2.2	26
63	Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade. Journal of Nuclear Medicine, 2021, 62, 1638-1644.	2.8	26
64	Immunogenicity of targeted lentivectors. Oncotarget, 2014, 5, 704-715.	0.8	25
65	Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions. International Journal of Molecular Sciences, 2022, 23, 904.	1.8	25
66	Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis. Molecular Imaging and Biology, 2017, 19, 49-58.	1.3	24
67	Evaluation of [99mTc]Radiolabeled Macrophage Mannose Receptor-Specific Nanobodies for Targeting of Atherosclerotic Lesions in Mice. Molecular Imaging and Biology, 2018, 20, 260-267.	1.3	24
68	B7-1, IFNÎ³ and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma. International Journal of Cancer, 2000, 87, 539-547.	2.3	23
69	Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity. Immunobiology, 2017, 222, 807-813.	0.8	23
70	Claudinâ€1, Claudinâ€2 and Claudinâ€11 Genes Differentially Associate with Distinct Types of Antiâ€inflammatory Macrophages In vitro and with Parasiteâ€and Tumourâ€elicited Macrophages In vivo. Scandinavian Journal of Immunology, 2012, 75, 588-598.	1.3	22
71	Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors. Journal of Controlled Release, 2019, 314, 1-11.	4.8	22
72	The metastatic Tâ€cell hybridoma antigen/Pâ€selectin glycoprotein ligand 1 is required for hematogenous metastasis of lymphomas. International Journal of Cancer, 2007, 121, 2646-2652.	2.3	20

#	Article	IF	Citations
73	A Novel Soluble Immune-Type Receptor (SITR) in Teleost Fish: Carp SITR Is Involved in the Nitric Oxide-Mediated Response to a Protozoan Parasite. PLoS ONE, 2011, 6, e15986.	1.1	18
74	Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha. Frontiers in Immunology, 2021, 12, 777524.	2.2	18
75	Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production. Vaccines, 2019, 7, 85.	2.1	17
76	The transduction pattern of ILâ€12â€encoding lentiviral vectors shapes the immunological outcome. European Journal of Immunology, 2015, 45, 3351-3361.	1.6	14
77	Reprint of: The non-mammalian MIF superfamily. Immunobiology, 2017, 222, 858-867.	0.8	12
78	Specificity Evaluation and Disease Monitoring in Arthritis Imaging with Complement Receptor of the Ig superfamily targeting Nanobodies. Scientific Reports, 2016, 6, 35966.	1.6	11
79	Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery. Gene Therapy, 2017, 24, 370-375.	2.3	11
80	NIRF-Molecular Imaging with Synovial Macrophages-Targeting Vsig4 Nanobody for Disease Monitoring in a Mouse Model of Arthritis. International Journal of Molecular Sciences, 2019, 20, 3347.	1.8	11
81	Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 1395.	2.2	11
82	Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade. Molecular Therapy - Methods and Clinical Development, 2021, 22, 172-182.	1.8	11
83	In vivo Visualization of M2 Macrophages in the Myocardium After Myocardial Infarction (MI) Using 68Ga-NOTA-Anti-MMR Nb: Targeting Mannose Receptor (MR, CD206) on M2 Macrophages. Frontiers in Cardiovascular Medicine, 2022, 9, 889963.	1.1	7
84	Development and Characterization of Nanobodies Targeting the Kupffer Cell. Frontiers in Immunology, 2021, 12, 641819.	2.2	6
85	Phase I results of CAM-H2: Safety profile and tumor targeting in patients.. Journal of Clinical Oncology, 2018, 36, e13017-e13017.	0.8	6
86	Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer. EJNMMI Research, 2021, 11, 115.	1.1	5
87	Multiple effects of transfection with interleukin 2 and/or interferon gamma on the behavior of mouse T lymphoma cells. Clinical and Experimental Metastasis, 1997, 16, 447-459.	1.7	4
88	Lyophilization of NOTA-sdAbs: First step towards a cold diagnostic kit for 68Ga-labeling. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 166, 194-204.	2.0	4
89	68Ga-Labeling: Laying the Foundation for an Anti-Radiolytic Formulation for NOTA-sdAb PET Tracers. Pharmaceuticals, 2021, 14, 448.	1.7	3
90	E5 2:45 Glucan-binding properties of a cytolytic protein of Eisenia foetida earthworms. Developmental and Comparative Immunology, 1997, 21, 115.	1.0	2

#	Article	IF	Citations
91	Decorating sdAbs with Chelators: Effect of Conjugation on Biodistribution and Functionality. Pharmaceuticals, 2021, 14, 407.	1.7	2
92	Expression of the inhibitory CD200 receptor is associated with alternative macrophage activation. Cytokine, 2009, 48, 35.	1.4	1
93	Do-it-yourself: construction of a custom cDNA macroarray platform with high sensitivity and linear range. BMC Biotechnology, 2011, 11, 97.	1.7	1
94	Editorial. Immunobiology, 2012, 217, 1223-1224.	0.8	1
95	Classical and alternative activation of macrophages: different pathways of macrophage-mediated tumor promotion. , 2008, , 139-156.		1
96	Do monocytes use the novel adipocytokine Visfatin/NAMPT/PBEF1 to flip the HIV coreceptor switch?. Retrovirology, 2009, 6, .	0.9	0
97	African Trypanosomiasis as Paradigm for Involvement of the Mononuclear Phagocyte System in Pathogenicity During Parasite Infection. , 2014, , 349-374.		0
98	Effects of Altered Antigen Processing on T-Cell Responses Toward Murine T-Lymphomas. Advances in Experimental Medicine and Biology, 1998, 451, 211-215.	0.8	0